Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.57 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 11/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433868 | 0.86 | MAP3K14 (0.54) | MAP3K14TBK1MAPK1MAPK6 | |
| SCHEMBL15301682 | 0.86 | MAP3K14 (0.54) | MAP3K14TBK1MAPK1MAPK6 | |
| SCHEMBL15301513 | 0.84 | TBK1 (0.55) | MAP3K14TBK1CCNA2CDK2CCNA1 | |
| SCHEMBL459048 | 0.83 | TBK1 (0.73) | MAP3K14TBK1CCNA2CDK2CCNA1 | |
| SCHEMBL433161 | 0.82 | MAP3K14 (0.50) | MAP3K14TBK1MAPK1MAPK6 | |
| SCHEMBL433159 | 0.82 | MAP3K14 (0.50) | MAP3K14TBK1MAPK1MAPK6 | |
| SCHEMBL435042 | 0.82 | TBK1 (0.53) | MAP3K14TBK1CCNA2CDK2CCNA1 | |
| SCHEMBL434250 | 0.82 | TBK1 (0.58) | MAP3K14TBK1MAPK1CCNA2CDK2 | |
| SCHEMBL432472 | 0.81 | TBK1 (0.65) | TBK1CCNA2CDK2CCNA1 | |
| SCHEMBL435440 | 0.81 | TBK1 (0.65) | TBK1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595964-B1 | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | DOMAINEX LTD (GB) | 2015-04-29 | — | — | EP | claimed |
| US-8962609-B2 | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | DOMAINEX LIMITED (GB) | 2015-02-24 | — | — | US | claimed |
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2013-10-10 | — | — | US | claimed |
| EP-2595964-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Domainex Limited (GB) | 2013-05-29 | — | — | EP | claimed |
| WO-2012010826-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2012-01-26 | — | — | WO | claimed |
| US-20230286924-A1 | CRYSTALLINE FORMS OF 4-(7-HYDROXY-2-ISOPROPYL-4-OXO-4H-QUINAZOLIN-3-YL)-BENZONITRILE AND FORMULATIONS THEREOF | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| EP-4192466-A1 | CRYSTALLINE FORMS OF 4-(7-HYDROXY-2-ISOPROPYL-4-OXO-4H-QUINAZOLIN-3-YL)-BENZONITRILE AND FORMULATIONS THEREOF | Novartis AG (CH) | 2023-06-14 | — | — | EP | disclosed |
| US-20230139170-A1 | Formulations of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2023-05-04 | — | — | US | disclosed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| US-20220162170-A1 | CRYSTALLINE FORMS OF 4-(7-HYDROXY-2-ISOPROPYL-4-OXO-4H-QUINAZOLIN-3-YL)-BENZONITRILE AND FORMULATIONS THEREOF | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2022-05-26 | — | — | US | disclosed |
| EP-3924345-A1 | CRYSTALLINE FORMS OF 4-(7-HYDROXY-2-ISOPROPYL-4-OXO-4H-QUINAZOLIN-3-YL)-BENZONITRILE AND FORMULATIONS THEREOF | Novartis AG (CH) | 2021-12-22 | — | — | EP | disclosed |
| EP-3923912-A1 | FORMULATIONS OF 4-(7-HYDROXY-2-ISOPROPYL-4-OXO-4H-QUINAZOLIN-3-YL)-BENZONITRILE | Novartis AG (CH) | 2021-12-22 | — | — | EP | disclosed |
| US-20130264007-A1 | PROCESS FOR PRODUCTION OF FINELY FIBROUS CELLULOSE COMPOSITE PREPREG SHEET, PROCESS FOR PRODUCTION OF FINELY FIBROUS CELLULOSE COMPOSITE SHEET, AND PROCESS FOR PRODUCTION OF FINELY FIBROUS CELLULOSE COMPOSITE LAMINATE SHEET | Oji Holdings Corporation (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| EP-2595964-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Domainex Limited (GB) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012010826-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012010826-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2012-01-26 | — | — | WO | disclosed |
| CN-100502832-C | Hair care composition | UNILEVER NV (NL) | 2009-06-24 | — | — | CN | disclosed |
| CN-1870970-A | Hair care composition | UNILEVER NV (NL) | 2006-11-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139170-A1 | Formulations of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile | HRH4, AQP4, P2RY4 | MAP3K14 2015/4885TBK1 470/4885MAPK1 2984/4885 |
| US-20220162170-A1 | CRYSTALLINE FORMS OF 4-(7-HYDROXY-2-ISOPROPYL-4-OXO-4H-QUINAZOLIN-3-YL)-BENZONITRILE AND FORMULATIONS THEREOF | P2RY4, P2RX4, AQP4 | MAP3K14 2201/4885TBK1 262/4885MAPK1 2816/4885 |
| US-20230286924-A1 | CRYSTALLINE FORMS OF 4-(7-HYDROXY-2-ISOPROPYL-4-OXO-4H-QUINAZOLIN-3-YL)-BENZONITRILE AND FORMULATIONS THEREOF | P2RY4, AQP4, P2RX4 | MAP3K14 2163/4885TBK1 276/4885MAPK1 2834/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | MAP3K14 1195/4885TBK1 1239/4885MAPK1 1617/4885 |
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CHUK, IKBKE, TBKBP1 | MAP3K14 101/4885TBK1 10/4885MAPK1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.